Tradjenta
Payments companies reported to CMS as associated with Tradjenta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tradjenta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tradjenta
These are the largest totals companies reported as associated with Tradjenta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| William Tamborlane | New Haven, CT | Pediatric Endocrinology | $18,000.00 |
| Ahmed Kolkailah | Chicago, IL | Internal Medicine | $4,047.31 |
| Julio Rosenstock | Dallas, TX | Endocrinology, Diabetes & Metabolism | $4,047.31 |
| Darren Mcguire | Dallas, TX | Cardiovascular Disease | $4,047.31 |
| Francine Welty | Boston, MA | Cardiovascular Disease | $3,250.00 |
| Robert Toto | Dallas, TX | Nephrology (Internal Medicine) | $1,724.52 |
| John Alexander | Durham, NC | Cardiovascular Disease | $1,724.52 |
| Rauf Baba | Dyersburg, TN | Endocrinology, Diabetes & Metabolism | $623.79 |
| Paul Azer | Beverly Hills, CA | $579.23 | |
| Reza Nazemi | Beverly Hills, CA | Endocrinology, Diabetes & Metabolism | $547.59 |
Prescribed Tradjenta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.